Moderna Chalks Up Industry Milestone With mRNA Cancer Vaccine Efficacy Success

 
• By Joseph Haas

Phase IIb KEYNOTE-942 study shows mRNA-4157/V940 paired with Keytruda reduces risk of recurrence and death in post-surgical melanoma patients compared with Keytruda alone.

Moderna
Moderna gets key data for its personalized cancer vaccine • Source: Shutterstock

More from Clinical Trials

More from R&D